MA29450B1 - Forme cristalline d'un derive de maleate de benzazepinium - Google Patents

Forme cristalline d'un derive de maleate de benzazepinium

Info

Publication number
MA29450B1
MA29450B1 MA30372A MA30372A MA29450B1 MA 29450 B1 MA29450 B1 MA 29450B1 MA 30372 A MA30372 A MA 30372A MA 30372 A MA30372 A MA 30372A MA 29450 B1 MA29450 B1 MA 29450B1
Authority
MA
Morocco
Prior art keywords
crystalline form
benzazepinium
maleate derivative
benzazepinium maleate
derivative
Prior art date
Application number
MA30372A
Other languages
English (en)
Inventor
Celine Bret
Sarah Jane Burgess
Simon John Hollas
Ian James King
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29450B1 publication Critical patent/MA29450B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE NOUVELLE FORME POLYMORPHE DE MALÉATE DE 7-[4-(4-CHLOROBENZYLOXY)BENZÈNESULFONYL]-8-MÉTHOXY-3-MÉTHYL-2,3,4,5-TÉTRAHYDRO-1H-3-BENZAZÉPINIUM ET UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE CORRESPONDANT, UNE PRÉPARATION PHARMACEUTIQUE, UN PROCÉDÉ POUR SA PRÉPARATION AINSI QUE SON UTILISATION À DES FINS MÉDICALES, NOTAMMENT COMME AGENT ANTIPSYCHOTIQUE
MA30372A 2005-05-24 2007-11-15 Forme cristalline d'un derive de maleate de benzazepinium MA29450B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0510599.4A GB0510599D0 (en) 2005-05-24 2005-05-24 Novel compounds

Publications (1)

Publication Number Publication Date
MA29450B1 true MA29450B1 (fr) 2008-05-02

Family

ID=34834575

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30372A MA29450B1 (fr) 2005-05-24 2007-11-15 Forme cristalline d'un derive de maleate de benzazepinium

Country Status (15)

Country Link
US (1) US20090163475A1 (fr)
EP (1) EP1885699A1 (fr)
JP (1) JP2008542222A (fr)
KR (1) KR20080011400A (fr)
CN (1) CN101184735A (fr)
AU (1) AU2006251330A1 (fr)
BR (1) BRPI0611479A2 (fr)
CA (1) CA2609489A1 (fr)
EA (1) EA200702596A1 (fr)
GB (1) GB0510599D0 (fr)
IL (1) IL187326A0 (fr)
MA (1) MA29450B1 (fr)
MX (1) MX2007014861A (fr)
NO (1) NO20076594L (fr)
WO (1) WO2006125622A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2970502A1 (fr) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Induction du gdnf pour le traitement de troubles de la retine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133587A (en) * 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
MX2007014861A (es) 2008-02-15
NO20076594L (no) 2007-12-20
US20090163475A1 (en) 2009-06-25
AU2006251330A1 (en) 2006-11-30
CA2609489A1 (fr) 2006-11-30
WO2006125622A1 (fr) 2006-11-30
IL187326A0 (en) 2008-04-13
EA200702596A1 (ru) 2008-04-28
KR20080011400A (ko) 2008-02-04
JP2008542222A (ja) 2008-11-27
EP1885699A1 (fr) 2008-02-13
CN101184735A (zh) 2008-05-21
BRPI0611479A2 (pt) 2010-09-14
GB0510599D0 (en) 2005-06-29

Similar Documents

Publication Publication Date Title
AP1635A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
LU91761I2 (fr) Vernakalant et ses dérivés pharmaceutiquement acceptables et en particulier son sel d'hydrochlorure (BRINAVESS®)
MA29403B1 (fr) Forme cristalline d'un compose quinolinone-carboxamide
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
SE9904508D0 (sv) New compounds
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
WO2007143523A3 (fr) Sulfonamides tricycliques condensés inhibiteurs de gamma-secrétase
EP1276480A4 (fr) Procede de fabrication d'enantiomeres de bupivacaine racemique, de compositions pharmaceutiques de bupivacaine, ces compositions pharmaceutiques de bupivacaine formulees sur sa base libre ou ses sels pharmaceutiquement acceptables et utilisation de ces compositions
MA27702A1 (fr) Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation
YU78302A (sh) Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja
MA27133A1 (fr) Nouvelles formes polymorphes cristallines d'hydrochlorure de lercanidipine et procede de fabrication associe
ATE318266T1 (de) 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
EA200100301A2 (ru) НОВЫЙ СПОСОБ ПОЛУЧЕНИЯ 11-АМИНО-3-ХЛОР-6,11-ДИГИДРО-5,5-ДИОКСО-6-МЕТИЛДИБЕНЗО[c,f][1,2]ТИАЗЕПИНА И ЕГО ПРИМЕНЕНИЕ ДЛЯ СИНТЕЗА ТИАНЕПТИНА
HUP0303662A2 (hu) Laktámvegyületek és alkalmazásuk szerin proteázok inhibitoraiként és ezeket tartalmazó gyógyszerkészítmények
TW200735878A (en) Pharmaceutical compositions
RU2005128828A (ru) Бензофураноксиэтиламины в качестве антидепрессантов и транквилизаторов
UA83870C2 (ru) Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1
PT1430034E (pt) Derivados de alquilaminopiridazinona substituida processo para sua preparacao e composicoes farmaceuticas que os contem
BR9911079A (pt) Acentuador de acetilcolina, composto, processo tanto para inibir a acetilcolina esterase de enzima quanto para antagonizar o receptor de serotonina 5ht3, e, composição farmacêutica.